Browsing by Author "Karakus, V"
Now showing 1 - 12 of 12
Results Per Page
Sort Options
Item Retrospective and multicenter analysis of efficacy and safety of ruxolitinib in 176 Turkish patients with myelofibrosis: updated dataSoyer, N; Ali, R; Turgut, M; Haznedaroglu, I; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Ozgur, G; Kis, C; Ceran, F; Ilhan, G; Ozkan, M; Arslaner, M; Ince, IItem EFFICACY AND SAFETY OF RUXOLITINIB IN TURKISH PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A MULTICENTER AND RETROSPECTIVE ANALYSISSoyer, N; Turgut, M; Haznedaroglu, I; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Ozgur, G; Kis, C; Ceran, F; Ilhan, G; Ozkan, M; Arslaner, M; Ince, I; Yavasoglu, IItem Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in TurkeySoyer, N; Ali, R; Turgut, M; Haznedaroglu, IC; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Özgür, G; Kis, C; Ceran, F; Ilhan, G; Özkan, M; Aslaner, M; Ince, I; Yavasoglu, I; Gediz, F; Sönmez, M; Güvenç, B; Özet, G; Kaya, E; Vural, F; Sahin, F; Töbü, M; Durusoy, R; Saydam, GBackground/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.Item Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 studyAkpinar, S; Tekgunduz, E; Esen, R; Yilmaz, M; Karakus, V; Vural, F; Gediz, F; Aydogdu, I; Kaynar, L; Goker, H; Kelkitli, E; Ayyildiz, O; Demirkan, FTo understand who uses social media and how often they do so, we examined the personality traits that predict frequency of using a set of 10 different types of social media (e.g., social networks, blogs, virtual worlds). Using survey data collected from two large-scale samples of young adults (Exploratory Study 1 N = 1586, Confirmatory Study 2 N =1432), we conducted direct replications of our findings to test whether the observed relationships between social media use and personality traits were reliable. Our replicated findings reveal that sex, age and extraversion are reliable predictors of several types of social media use (e.g., Facebook, Messaging Platforms, Online Forums), while other traits (e.g., agreeableness, Machiavellianism) showed unreliable associations. Our findings also reveal dimensions of multiplatform social media use that categorize the media ecologies of young adults and show significant associations with individual difference measures. (C) 2020 Published by Elsevier Inc.Item The outcome of eltrombopag therapy in immune thrombocytopenia: a multicenter study from TurkeyPamuk, GE; Maden, M; Sari, HI; Erkurt, MA; Keskinkilic, M; Cagliyan, GA; Kaya, AH; Sincan, G; Turak, ET; Ilkkilic, K; Kuku, I; Aydogdu, I; Tekgunduz, E; Sencan, M; Albayrak, M; Berber, I; Karakus, V; Gemici, AI; Korkmaz, S; Keskin, A; Eser, B; Altuntas, FItem Acquired Hemophilia A In Adults: A Multicenter Study from TurkeyDavulcu, EA; Demirci, Z; Yilmaz, U; Ar, MC; Teke, HÜ; Karakus, V; Çiftçiler, R; Selim, C; Yavasoglu, I; Durusoy, SS; Okan, V; Akdeniz, A; Yolcu, A; Aydogdu, I; Güney, T; Yilmaz, AF; Sahin, FAcquired hemophilia A (AHA) is a rare disease caused by autoantibodies inhibiting factor VIII (FVIII) activity. Although the conditionis usually idiopathic, there may be other underlying diseases. Treatment consists of two steps: treatment of acute bleeding and immunosuppression. In this multicenter study, we aimed to demonstrate the clinical characteristics, management details, and survival of AHA patients in Turkey. Data was collected from eleven centers in Turkey. aPTT, FVIII, FVIII inhibitor, and hemoglobin (HB) levels, mixing test results, and demographics at diagnosis, treatment information, adverse events, bleeding episodes during follow-up, relapses, and outcome were analyzed. Twenty-nine patients were analyzed (58.6% female). No underlying disorder could be detected in 14 patients. The most prevalent etiologies were pregnancy, malignancy and infections. The median FVIII activity and FVIII inhibitor titer at diagnosis were 0.7% (0.0-29.4%) and 32.6 BU (0.6-135.6 BU) respectively. Bleeding was severe in 44.8% of patients. The HB value was significantly lower in patients with severe bleeding. Most of the patients (n = 25, 86.2%) had only one bleeding episode without relapse, three patients (10.3%) had two bleeding episodes, and one patient had more than three bleedings. 21 (75%) patients received hemostatic therapy. The use of recombinant FVIIa was slightly higher than activated prothrombin complex concentrate (15 versus 10 patients). Immunosuppressive treatment was initiated in 26 (93%) patients. Regimens containing steroid, cyclophosphamide, and rituximab in different combinations were the most preferred. The median follow-up period was 13 months (2-156 months). Median overall survival was 154.97 months. Four and six-year survival were 90.9 +/- 0.8% and 77.9 +/- 14.1% respectively. This is a unique study that investigated the demographic characteristics, treatment approaches, and patient survival of AHA in Turkey.Item Evolution of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in turkey: a multicenter retrospective analysisKaradag, FK; Yenerel, MN; Yilmaz, M; Uskudar, H; Ozkocaman, V; Tuglular, TF; Erdem, F; Unal, A; Ayyildiz, O; Ozet, G; Comert, M; Kaya, E; Ayer, M; Salim, O; Guvenc, B; Ozdogu, H; Mehtap, O; Sonmez, M; Guler, N; Hacioglu, S; Aydogdu, I; Bektas, O; Toprak, SK; Kaynar, L; Yagci, M; Aksu, S; Tombak, A; Karakus, V; Yavasoglu, I; Onec, B; Ozcan, MA; Undar, L; Ali, R; Ilhan, O; Saydam, G; Sahin, FParoxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab approved with promising results for PNH patients. We conducted this study to evaluate the long term experience of eculizumab therapy from Turkey for the first time. Our cohort included 138 patients with PNH treated with eculizumab between January 2008 and December 2018 at 28 centers in Turkey. Laboratory and clinical findings at the time of diagnosis and after eculizumab therapy were recorded retrospectively. The median age was 39 (range 18-84) years and median granulocyte PNH clone size was 74% (range 3.06-99.84%) at the time of diagnosis. PNH with bone marrow failure syndrome was detected in 49 patients and the rest of 89 patients had classical PNH. Overall 45 patients (32.6%) had a history of any prior thrombotic event before eculizumab therapy and only 2 thrombotic events were reported during the study period. Most common symptoms are fatigue (75.3%), hemoglobinuria (18.1%), abdominal pain (15.2%) and dysphagia (7.9%). Although PNH is commonly related with coombs negativity, we detected coombs positivity in 2.17% of patients. Seven months after the therapy, increased hemoglobin level was seen and remarkably improvement of lactate dehydrogenase level during the treatment was occurred. In addition to previous studies, our real life data support that eculizumab is well tolerated with no serious adverse events and improves the PNH related findings.Item Prospective Real-World Outcomes of Acute Myeloid LeukemiaKarakus, V; Iltar, U; Yenihayat, EM; Polat, MG; Celik, S; Malkan, UY; Seval, GC; Dogan, A; Akdeniz, A; Pinar, IE; Ozdalci, D; Ince, I; Erdem, R; Mehtap, O; Kirkizlar, HO; Kacmaz, M; Deveci, B; Aykas, F; Akat, GK; Kaya, SY; Ozturk, HBA; Sevindik, O; Can, F; Cekdemir, D; Aslan, C; Bulbul, H; Guven, ZT; Maral, S; Durusoy, SS; Demirkan, F; Goker, H; Ozkalemkas, F; Keklik, M; Toprak, SK; Yucel, EE; Atas, U; Alacacioglu, IItem Acute Myeloid Leukemia in Elderly, Unfit Patients: Analysis of Turkish AML Prospective Registry Database, on Behalf of Acute Leukemia Working Group of Turkish Society of HematologyUrlu, SM; Seval, GC; Yücel, EE; Mehtap, O; Yenihayat, EM; Polat, MG; Malkan, UY; Ozbalci, D; Kaya, SY; Durusoy, SS; Akdeniz, A; Kirkizlar, O; Dogan, A; Pinar, IE; Kacmaz, M; Ozturk, HBA; Atas, U; Deveci, B; Akat, GK; Guven, ZT; Sevindik, OG; Demirkan, F; Alacacioglu, I; Karakus, VItem A Multicenter Experience of Thrombotic Microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 StudyTekgunduz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Pamuk, GE; Altuntas, F; Sari, HI; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, FItem A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 studyTekgündüz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Altuntas, F; Sari, I; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, FThrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular thrombosis and tissue ischemia. The differentiation of the etiology is of utmost importance as the pathophysiological basis will dictate the choice of appropriate treatment. We retrospectively evaluated 154 (99 females and 55 males) patients who received therapeutic plasma exchange (TPE) due to a presumptive diagnosis of TMA, who had serum ADAMTSI3 activity/antiADAMTS13 antibody analysis at the time of hospital admission. The median age of the study cohort was 36 (14-84). 67 (43.5%), 32 (20.8%), 27 (17.5%) and 28 (18.2%) patients were diagnosed as thrombotic thrombocytopenic purpura (TTP), infection/complement-associated hemolytic uremic syndrome (IA/CAHUS), secondary TMA and TMA-not otherwise specified (TMA-NOS), respectively. Patients received a median of 18 (1-75) plasma volume exchanges for 14 (153) days. 81 (52.6%) patients received concomitant steroid therapy with TPE. Treatment responses could be evaluated in 137 patients. 90 patients (65.7%) achieved clinical remission following TPE, while 47 (34.3%) patients had non-responsive disease. 25 (18.2%) non-responsive patients died during follow-up. Our study present real-life data on the distribution and follow-up of patients with TMAs who were referred to therapeutic apheresis centers for the application of TPE. (C) 2018 Elsevier Ltd. All rights reserved.Item Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from TurkeyKaradag, FK; Yenerel, MN; Mehmet, Y; Teke, HU; Ozkocaman, V; Tuglular, T; Erdem, F; Unal, A; Ayyildiz, O; Ozet, G; Ozkan, M; Kaya, E; Ayer, M; Salim, O; Güvenç, B; Ozdogu, H; Mehtap, Ö; Sönmez, M; Güler, N; Hacioglu, SK; Aydogdu, I; Bektas, O; Toprak, SK; Kaynar, L; Yagci, M; Aksu, S; Tombak, A; Karakus, V; Yavasoglu, I; Öneç, B; Özcan, MA; Ündar, L; Ali, R; Ustun, C; Ilhan, O; Saydam, G; Sahin, F